Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are: * Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins? * Will the use of UDCA decrease other adverse events in patients taking oral statins? Participants will: * Take Atorvastatin combined with UDCA or a placebo daily for 6 months * Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Age 18-75 years old.

• LDL-C≥3.4mmol/l (130 mg/dL).

• Glycosylated hemoglobin ≤ 6.0% (42 mmol/mol).

• Voluntarily sign informed consent.

Locations
Other Locations
China
Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING
Xi'an
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITING
Xi'an
Contact Information
Primary
Yue Yu
yueyu05@163.com
0086-85323810
Backup
Yue Wu, Professor
imyuewu@qq.com
0086-029-8532-3664
Time Frame
Start Date: 2024-11-25
Estimated Completion Date: 2027-06-01
Participants
Target number of participants: 128
Treatments
Experimental: Ursodeoxycholic acid group
Ursodeoxycholic acid (UDCA) 500 mg: This group of participants receive UDCA 500mg per day.
Placebo_comparator: placebo group
This group of participants receive placebo.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital Xi'an Jiaotong University

This content was sourced from clinicaltrials.gov